Table 1

Characteristics of the Iranian cohort studies included in the pooling project to define prediction models for CVD mortality

Study baseline199920022001200420102009
Study populationUrbanUrbanUrban–RuralUrban–RuralUrban–RuralUrban
LocationTehranTehranIsfahan, Najafabad, ArakGonbad, Kalaleh,
Gonbad, Kalaleh,
Age range, years≥3≥3≥3540–7545–8040–64
Baseline cohort size, n15 0053550650450 04511 418*5190
Rural population, %27.5276.1081.14
Women, n (%)55.9450.5451.2957.5752.4658.55
Included in the current study†4809927508345 88910 2294583
Women, n (%)2723 (56.6)449 (48.4)2605 (51.3)26 378 (57.5)5412 (52.9)2726 (59.5)
Median follow-up (IQR), years14.1 (13.6–14.6)9.6 (9.0–9.9)11.3 (10.9–12.3)9.1 (8.0–10.0)4.5 (3.9–5.0)5.0 (4.8–5.2)
No follow-up, n476217035200‡
  • *This sample is a subgroup of GCS1.

  • † Participants aged 40–80 years and free of CVD at baseline were included in the current study.

  • ‡Three hundred and forty-five individuals had no information of both CVD history at baseline and follow-up, so they were excluded as unknown CVD.

  • CVD, cardiovascular disease; GCS1, Golestan Cohort Study phase 1; GCS2, Golestan Cohort Study phase 2; ICS, Isfahan Cohort Study; ShECS, Shahroud Eye Cohort Study; TLGS1, Tehran Lipid and Glucose Study phase 1; TLGS2, Tehran Lipid and Glucose Study—new recruited individuals in phase 2.